Have a feature idea you'd love to see implemented?
Let us know!
RPTX Repare Therapeutics Inc
Price (delayed)
$1.32
Market cap
$56.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.99
Enterprise value
-$21.86M
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled
Highlights
RPTX's debt is down by 35% year-on-year but it is up by 18% since the previous quarter
RPTX's net income is down by 23% since the previous quarter but it is up by 14% year-on-year
The equity has contracted by 25% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of RPTX
Market
Valuations
Earnings
Shares outstanding
42.51M
Market cap
$56.11M
Enterprise value
-$21.86M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.32
Price to sales (P/S)
0.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.33
Revenue
$66.52M
Gross profit
$66.52M
Net income
-$84.05M
EBIT
-$82.42M
EBITDA
-$78.08M
Free cash flow
-$77.68M
Per share
Balance sheet
Liquidity
EPS
-$1.99
EPS diluted
-$2
Free cash flow per share
-$1.83
Book value per share
$4.12
Revenue per share
$1.57
TBVPS
$4.86
Total assets
$206.39M
Total liabilities
$31.43M
Debt
$2.56M
Equity
$174.96M
Working capital
$169.32M
Debt to equity
0.01
Current ratio
6.45
Quick ratio
5.88
Net debt/EBITDA
1
Margins
Efficiency
Dividend
EBITDA margin
-117.4%
Gross margin
100%
Net margin
-126.3%
Operating margin
-140.9%
Return on assets
-35.1%
Return on equity
-40.9%
Return on invested capital
-71.3%
Return on capital employed
-47%
Return on sales
-123.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RPTX stock price
How has the Repare Therapeutics stock price performed over time
Intraday
0.76%
1 week
0%
1 month
-58.75%
1 year
-81.89%
YTD
0.76%
QTD
0.76%
Financial performance
How have Repare Therapeutics's revenue and profit performed over time
Revenue
$66.52M
Gross profit
$66.52M
Operating income
-$93.74M
Net income
-$84.05M
Gross margin
100%
Net margin
-126.3%
RPTX's net margin is up by 27% year-on-year but it is down by 27% since the previous quarter
Repare Therapeutics's operating margin has increased by 24% YoY
RPTX's net income is down by 23% since the previous quarter but it is up by 14% year-on-year
Repare Therapeutics's revenue has increased by 18% YoY but it has decreased by 3.1% from the previous quarter
Growth
What is Repare Therapeutics's growth rate over time
Valuation
What is Repare Therapeutics stock price valuation
P/E
N/A
P/B
0.32
P/S
0.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.33
RPTX's EPS is down by 22% from the previous quarter but it is up by 14% YoY
The P/B is 88% below the 5-year quarterly average of 2.6 and 68% below the last 4 quarters average of 1.0
The equity has contracted by 25% YoY and by 14% from the previous quarter
The P/S is 100% lower than the 5-year quarterly average of 767.0 and 73% lower than the last 4 quarters average of 3.1
Repare Therapeutics's revenue has increased by 18% YoY but it has decreased by 3.1% from the previous quarter
Efficiency
How efficient is Repare Therapeutics business performance
The ROA has contracted by 33% from the previous quarter and by 16% YoY
RPTX's return on equity is down by 32% since the previous quarter and by 6% year-on-year
RPTX's ROS is up by 24% YoY
Repare Therapeutics's ROIC has decreased by 6% from the previous quarter and by 5% YoY
Dividends
What is RPTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RPTX.
Financial health
How did Repare Therapeutics financials performed over time
Repare Therapeutics's total liabilities has decreased by 41% YoY
The company's total assets fell by 28% YoY and by 12% QoQ
RPTX's debt is 99% smaller than its equity
The debt to equity has dropped by 50% year-on-year
RPTX's debt is down by 35% year-on-year but it is up by 18% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.